Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
59
datasets available to search
ShareScore release 0.9.0
Dataset results
59 results for “HIV prevalence”
Population size, HIV prevalence, and antiretroviral therapy coverage among key populations in sub-Saharan Africa: collation and synthesis of survey data 2010-2023
<p>This dataset contains surveillance study estimates for population size, HIV prevalence, and ART coverage among female sex workers (FSW), men who have sex with men (MSM), people who inject drugs (PWID), and transgender men and women (TGM/W) from 2010-2023. It was created to support the UNAIDS Estimates Key Population Workbook for use by HIV estimates teams in sub-Saharan Africa. Key population surveillance reports, including Ministry of Health-led biobehavioural surveys, mapping studies, and academic studies were used to populate the database.</p> <p>The dataset was populated using existing key population size estimate databases including:</p> <ul> <li>UNAIDS Key Population Atlas</li> <li>US Centers for Disease Control and Prevention surveillance database</li> <li>Global Fund against HIV/AIDS, TB, and Malaria surveillance database</li> <li>Global.HIV database</li> <li>Systematic review databases among MSM (<a href="https://pubmed.ncbi.nlm.nih.gov/31601542/" target="_blank" rel="noopener">Stannah et al, 2019</a> and <a href="https://pubmed.ncbi.nlm.nih.gov/37453439/" target="_blank" rel="noopener">Stannah et al., 2023</a>) and PWID (<a href="https://pubmed.ncbi.nlm.nih.gov/36996857/" target="_blank" rel="noopener">Degenhardt et al., 2023</a>)</li> </ul> <p><br>and was additionally supplemented by a literature review of peer-reviewed and grey literature sources.</p> <p>The data can be <a href="https://shiny.dide.ic.ac.uk/kp-data/" target="_blank" rel="noopener">explored in this web application</a> and the <a href="https://www.medrxiv.org/content/10.1101/2022.07.27.22278071v3" target="_blank" rel="noopener">accompanying manuscript can be found here</a></p>
Characteristics and Prevalence of Tuberculosis and HIV in Masiphumelele Township, Cape Town, South Africa
ClinicalTrials.gov study NCT00346476. IPD Sharing: Not stated. Countries: 1. Publications: 7.
Prevalence and Predictors of Neurocognitive Impairment Among HIV-infected Patients
ClinicalTrials.gov study NCT00893815. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Data from: Global prevalence and burden of HIV-associated neurocognitive disorder: a meta-analysis
<p>Objectives: We aimed to characterise the prevalence and burden of HAND and assess associated factors in the global population with HIV.</p> <p>Methods: We searched PubMed and Embase for cross-sectional or cohort studies reporting the prevalence of HAND or its subtypes in HIV-infected adult populations from Jan 1, 1996, to May 15, 2020, without language restrictions. Two reviewers independently undertook the study selection, data extraction, and quality assessment. We estimated pooled prevalence of HAND by a random effects model and evaluated its overall burden worldwide.</p> <p>Results: Of 5588 records identified, we included 123 studies involving 35513 participants from 32 countries. The overall prevalence of HAND was 42·6% (95% CI: 39·7-45·5), and did not differ with respect to diagnostic criteria used. The prevalence of asymptomatic neurocognitive impairment (ANI), mild neurocognitive disorder (MND) and HIV-associated dementia (HAD) were 23·5% (20·3-26·8), 13·3% (10·6-16·3) and 5·0% (3·5-6·8) according to the Frascati criteria, respectively. The prevalence of HAND was significantly associated with the level of CD4 nadir, with a prevalence of HAND higher in low CD4 nadir groups (mean/median CD4 nadir <200: 45·2%, 40·5-49·9) versus high CD4 nadir group (mean/median CD4 nadir ≥200: 37·1%, 32·7-41·7). Worldwide, we estimated that there were roughly 16145400 (95% CI 15046300-17244500) cases of HAND in HIV-infected adults, with 72% in sub-Saharan Africa (11571200 cases, 95% CI 9600000-13568000).</p> <p>Conclusions: Our findings suggest that people living with HIV have a high burden of HAND in the ART era, especially in sub-Saharan Africa and Latin America. Earlier initiation of ART and sustained adherence to maintain a high level CD4 cell count and prevent severe immunosuppression is likely to reduce the prevalence and severity of HAND.</p>
Prevalence, severity, and risk factors of disability among adults living with HIV accessing routine outpatient HIV care in London, United Kingdom (UK): A cross-sectional self-report study
<div> <p><strong>Background</strong></p> <p>The study objectives were to measure disability prevalence and severity, and examine disability risk factors, among adults living with HIV in London, United Kingdom (UK).</p> <p><strong>Methods</strong></p> <p>Self-reported questionnaires were administered: World Health Organization Disability Assessment Schedule 2.0 (WHODAS), HIV Disability Questionnaire (HDQ), Equality Act disability definition (EADD), and demographic questionnaire. We calculated proportion (95% Confidence Interval; CI) of "severe" and "moderate" disability measured using EADD and WHODAS scores ≥2 respectively. We measured disability severity with HDQ domain severity scores. We used demographic questionnaire responses to assess risk factors of "severe" and "moderate" disability using logistic regression analysis, and HDQ severity domain scores using linear regression analysis.</p> <p><strong>Results</strong></p> <p>Of 201 participants, 176 (87.6%) identified as men, median age 47 years, and 194 (96.5%) virologically suppressed. Severe disability prevalence was 39.5% (n=79/201), 95% CI [32.5%, 46.4%]. Moderate disability prevalence was 70.5% (n=141/200), 95% CI [64.2%, 76.8%]. Uncertainty was the most severe HDQ disability domain. Late HIV diagnosis was a risk factor for severe disability [Odds Ratio (OR) 2.71; CI 1.25, 5.87]. Social determinants of health, economic inactivity [OR 2.79; CI 1.08, 7.21] and receiving benefits [OR 2.87; CI 1.05, 7.83], were risk factors for "severe" disability. <span>Economic inactivity [OR 3.14; CI 1.00, 9.98] was a risk factor for </span>"moderate" disability. Economic inactivity, receiving benefits, and having no fixed abode were risk factors (P≤0.05) across HDQ domains; physical, mental and emotional, difficulty with day-to-day activities, and challenges to social participation. Personal factors, identifying as a woman and being aged <50 years, were risk factors (P≤0.05) for HDQ domains; mental and emotional, uncertainty, and challenges with social participation.</p> <p><strong>Conclusions</strong></p> <p>People living with well-controlled HIV in London UK experienced multi-dimensional and episodic disability. Results help to better understand the prevalence, severity, and risk factors of disability experienced by adults living with HIV, identify areas to target interventions, and optimise health and functioning.</p> </div>
The Prevalence of Vitamin D Deficiency and Effects of Vitamin D Supplementation in HIV-1 Infected Patients
ClinicalTrials.gov study NCT00306410. IPD Sharing: Not stated. Countries: 1. Publications: 5.
Prevalence of Advanced Fibrosis in Patients Living With HIV
ClinicalTrials.gov study NCT04066608. IPD Sharing: NO. Countries: 1. Publications: 2.
The Prevalence of Oral HPV Infection and Oral Lesions in People Living With HIV
ClinicalTrials.gov study NCT06205511. IPD Sharing: UNDECIDED. Countries: 1. Publications: 11.
Prevalence,Knowledge and Attitude of HIV /AIDS in Luxor
ClinicalTrials.gov study NCT03485599. IPD Sharing: UNDECIDED. Countries: 1. Publications: 3.
Inhalation/Nasal Corticosteroids and Prevalence of Hypothalamic-pituitary-adrenal (HPA) Axis Suppression in Human Immunodeficiency Virus (HIV)-Patients
ClinicalTrials.gov study NCT02501486. IPD Sharing: Not stated. Countries: 1. Publications: 1.
The Prevalence of HIV Drug Resistance and Transmission Risk in Opioid Agonist Treatment
ClinicalTrials.gov study NCT00857350. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Prevalence and Pathogenesis of Lung Disease in a Large HIV Cohort-coordinating Center
ClinicalTrials.gov study NCT00870857. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Prevalence of HIV and Tuberculosis in Masiphumelele Township, Cape Town, South Africa
ClinicalTrials.gov study NCT00096681. IPD Sharing: Not stated. Countries: 0. Publications: 2.
Prevalence of HCV in HIV-negative MSM
ClinicalTrials.gov study NCT04005248. IPD Sharing: NO. Countries: 1. Publications: 3.
Enhanced TB Screening to Determine the Prevalence and Incidence of TB in Patients With HIV
ClinicalTrials.gov study NCT02043067. IPD Sharing: Not stated. Countries: 1. Publications: 25.
Incidence of Oral Candidiasis, Prevalence of C. Dubliniensis in HIV Patients and In-vitro Azole Susceptibility
ClinicalTrials.gov study NCT00692783. IPD Sharing: Not stated. Countries: 1. Publications: 6.
Determination of HCV Prevalence in a HIV Patient Cohort in Phnom Penh, Cambodia
ClinicalTrials.gov study NCT02361541. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Cancer Prevalence and Outcomes in Individuals With HIV and AIDS: Multicenter BUHASDER Study
ClinicalTrials.gov study NCT06774495. IPD Sharing: YES. Countries: 1. Publications: 4.
Prevalence, Characteristics and Risk Factors of HIV-Associated Neurocognitive Disorders in Subjects Between the Ages of 55 and 70 Years: An Exposed/Unexposed Cross Sectional Study
ClinicalTrials.gov study NCT02592174. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Estimation of the Prevalence of HIV, Hepatitis C and Hepatitis B Infection Among Detainees in the Nîmes Administrative Detention Center
ClinicalTrials.gov study NCT05127187. IPD Sharing: Not stated. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.